LC51 0255

Drug Profile

LC51 0255

Alternative Names: LC51-0255

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem
  • Class Anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 04 Jun 2017 LG Chem plans a phase I trial of LC51 0255 (In volunteers) in South Korea (PO) (NCT03174613)
  • 04 Jun 2017 Preclinical trials in Inflammation in South Korea (PO), before June 2017 (LG Chem website, June 2017)
  • 31 May 2017 Phase-I clinical trials in Inflammation (In volunteers) in South Korea (PO) (NCT03174613)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top